HeartSciences gets green light to sell next-gen ECG in EU

HeartSciences has started selling its MyoVista electrocardiograph (ECG) in Europe after picking up a CE mark. The device is designed to enable early detection of artery disease by visualizing energy distribution during cardiac cycles.

Traditional ECGs detect and display the electrical signals the heart produces when it beats. The low cost and safety of the test made it a go-to option for doctors. But the shortcomings of ECGs have seen organizations including U.K. cost watchdog NICE recommend against their use in certain situations. ECGs are particularly poor at detecting structural and ischemic heart disease.

Click here for the full story